"Genetic SD-card": Scientists obtained new methods to improve the genome editing system
Researchers take a step in the development of genome editing technology
Researchers from Peter the Great St.Petersburg Polytechnic University (SPbPU) in collaboration with colleagues from Belgium take a step in the development of genome editing technology. Currently it is possible to deliver genetic material of different sizes and structures to organs and tissues. This is the key to eliminating DNA defects and treating more patients. The project is guided by Professor Gleb Sukhorukov and supported by the Russian Science Foundation. Research results were published in Particle & Particle Systems Characterization journal.

Researchers take a step in the development of genome editing technology
Peter the Great St.Petersburg Polytechnic University
An international research group developed a polymer carrier with a number of unique properties, several types of genetic material can be loaded in its structure. In particular, the scientists managed to load genetic material of various sizes and structures into "universal containers". From small interfering RNAs (siRNAs) to messenger RNAs (mRNAs). The efficiency of delivery was demonstrated on human stem cells.
"Nowadays most of the vaccines, including those for COVID-19, are made on the basis of mRNA. This is a kind of "genetic SD-card" with information which activates human immune system, thus teaches it how to deal with the "enemy proteins" of the virus. Typically, for medical purposes, different types of carriers are used to deliver specific molecules, we proved that it is possible to deliver genetic materials of different sizes using one type of carrier. This technology opens up new horizons for the development of non-viral delivery systems", - notes Alexander Timin, head of the Laboratory for microencapsulation and controlled delivery of biologically active compounds at St. Petersburg Polytechnic University.
Scientists added that the micron-scaled carrier with incorporated genetic material can be delivered by systemic administration, or locally (directly into the tumor focus for cancer).
"The study is conducted jointly with the Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, which provided the patients'mesenchymal stem cells (cells building organs and tissues) for the experiments. In the future, we plan to conduct experiments on tumor-bearing laboratory animals in order to find out how the genetic material delivered to the tumor will be managed, "- said Igor Radchenko, director of the "RASA-Polytech" center.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Juniper_berry
BASF and universities jointly develop new process - Improvement of bioavailability of active ingredients
Two-Stage Amplifier Coupling two enzymatic reactions: sensitive detection for immunological ELISA tests
Fructose_1,6-bisphosphate
Genetics researchers develop more efficient method of making stem cells
Trichloroethylene
Max_Saenger

How a “date” between immune cells makes rheumatism disappear - Major success: New approach for treating autoimmune diseases
Category:Kinin_system
